Enrolling by invitationNCT06806956

Severe Malaria in Remote Areas- Closing the Evidence Gap

Studying Malaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tropical Diseases Research Centre, Zambia
Intervention
Treatment of severe malaria with either RAS + ACT or RAS + injectable artesunate + ACT will each achieve the clinically acceptable cure rate of 97% ± 5% in remote areas(drug)
Enrollment
2016 target
Eligibility
5 years · All sexes
Timeline
20242027

Study locations (2)

Collaborators

Universiteit Antwerpen · University of Kinshasa · National Institute for Medical Research, Tanzania · Medicines for Malaria Venture · Université de Lubumbashi

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06806956 on ClinicalTrials.gov

Other trials for Malaria

Additional recruiting or active studies for the same condition.

See all trials for Malaria

← Back to all trials